市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Curis, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 1.2 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | -2.0 |
| 相对估值 | NA |
| 财务健康 | -4.0 |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.11 |
|
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 8.64% |
| 机构持股比例 | 44.65% |
投资组合